Drug intelligence / Profile preview

BPM-PD-001

Development stage: Preclinical
Lead developer: Baiya Phytopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BPM-PD-001 is a preclinical-stage monoclonal antibody being developed by Baiya Phytopharm for the treatment of asthma. It functions as an anti-IgE antibody, designed to neutralize circulating Immunoglobulin E (IgE) and prevent its interaction with high-affinity receptors on effector cells such as mast cells and basophils. By neutralizing IgE, the drug aims to interrupt the allergic cascade that leads to airway inflammation and asthmatic symptoms. BPM-PD-001 is part of Baiya Phytopharm's pipeline of plant-produced biopharmaceuticals, utilizing their proprietary plant-based protein expression platform.

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on BPM-PD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPM-PD-001.